Mojcik CF[au] - Search Results

Year	Number of Results
1982	1
1987	1
1988	2
1991	1
1992	1
1993	1
1994	2
1995	2
1996	1
1997	2
1998	1
2001	1
2003	1
2004	5
2005	1
2006	2
2007	1
2017	1
2018	1
2026	0

1

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. Hillmen P, et al. Among authors: mojcik cf. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. N Engl J Med. 2006. PMID: 16990386 Free article. Clinical Trial.

2

Adhesion molecules: a rheumatologic perspective.

Mojcik CF, Shevach EM. Mojcik CF, et al. Arthritis Rheum. 1997 Jun;40(6):991-1004. doi: 10.1002/art.1780400602. Arthritis Rheum. 1997. PMID: 9182908 Review. No abstract available.

3

Aprotinin and the systemic inflammatory response after cardiopulmonary bypass.

Mojcik CF, Levy JH. Mojcik CF, et al. Ann Thorac Surg. 2001 Feb;71(2):745-54. doi: 10.1016/s0003-4975(00)02218-9. Ann Thorac Surg. 2001. PMID: 11235755 Review.

4

Role of endogenous retroviruses in autoimmune diseases.

Gourley MF, Kisch WJ, Mojcik CF, King LB, Krieg AM, Steinberg AD. Gourley MF, et al. Among authors: mojcik cf. Tohoku J Exp Med. 1994 May;173(1):105-14. doi: 10.1620/tjem.173.105. Tohoku J Exp Med. 1994. PMID: 7809902 Free article. Review.

5

End-stage renal disease and systemic lupus erythematosus.

Mojcik CF, Klippel JH. Mojcik CF, et al. Am J Med. 1996 Jul;101(1):100-7. doi: 10.1016/s0002-9343(96)00074-5. Am J Med. 1996. PMID: 8686702 Review.

6

Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.

Rother RP, Mojcik CF, McCroskery EW. Rother RP, et al. Among authors: mojcik cf. Lupus. 2004;13(5):328-34. doi: 10.1191/0961203303lu1021oa. Lupus. 2004. PMID: 15230287 Review.

7

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.

Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, Mojcik CF, Rother RP. Hill A, et al. Among authors: mojcik cf. Blood. 2005 Oct 1;106(7):2559-65. doi: 10.1182/blood-2005-02-0564. Epub 2005 Jun 28. Blood. 2005. PMID: 15985537 Free article. Clinical Trial.

8

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.

Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Rother RP, et al. Among authors: mojcik cf. Nat Biotechnol. 2007 Nov;25(11):1256-64. doi: 10.1038/nbt1344. Nat Biotechnol. 2007. PMID: 17989688

9

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Hillmen P, et al. Among authors: mojcik cf. N Engl J Med. 2004 Feb 5;350(6):552-9. doi: 10.1056/NEJMoa031688. N Engl J Med. 2004. PMID: 14762182 Free article. Clinical Trial.

10

Vascular cell adhesion molecule-1 is expressed by cortical thymic epithelial cells and mediates thymocyte adhesion. Implications for the function of alpha4beta1 (VLA4) integrin in T-cell development.

Salomon DR, Crisa L, Mojcik CF, Ishii JK, Klier G, Shevach EM. Salomon DR, et al. Among authors: mojcik cf. Blood. 1997 Apr 1;89(7):2461-71. Blood. 1997. PMID: 9116290 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year